Amalgamated Bank Sells 765 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Amalgamated Bank reduced its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 2.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 26,656 shares of the company’s stock after selling 765 shares during the period. Amalgamated Bank’s holdings in Myriad Genetics were worth $730,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. Hexagon Capital Partners LLC increased its position in Myriad Genetics by 75.3% in the 2nd quarter. Hexagon Capital Partners LLC now owns 1,143 shares of the company’s stock valued at $28,000 after acquiring an additional 491 shares in the last quarter. Innealta Capital LLC acquired a new stake in Myriad Genetics in the 2nd quarter valued at about $36,000. GAMMA Investing LLC increased its position in Myriad Genetics by 34.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,620 shares of the company’s stock valued at $44,000 after acquiring an additional 412 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in Myriad Genetics in the 2nd quarter valued at about $60,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Myriad Genetics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,285 shares of the company’s stock valued at $87,000 after acquiring an additional 583 shares in the last quarter. 99.02% of the stock is owned by institutional investors.

Myriad Genetics Stock Down 2.7 %

Myriad Genetics stock opened at $15.25 on Friday. The company’s 50 day simple moving average is $23.43 and its 200 day simple moving average is $24.60. Myriad Genetics, Inc. has a fifty-two week low of $15.18 and a fifty-two week high of $29.30. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of -11.73 and a beta of 1.93. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73.

Analysts Set New Price Targets

Several equities research analysts have weighed in on MYGN shares. StockNews.com upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating in a research report on Tuesday. TD Cowen lifted their price target on shares of Myriad Genetics from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Wednesday, August 7th. Morgan Stanley assumed coverage on shares of Myriad Genetics in a research report on Thursday, September 19th. They set an “equal weight” rating and a $32.00 price target for the company. Wells Fargo & Company assumed coverage on shares of Myriad Genetics in a research report on Tuesday, August 27th. They set an “overweight” rating and a $35.00 price target for the company. Finally, Piper Sandler lowered their price target on shares of Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating for the company in a research report on Monday, November 11th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Myriad Genetics currently has a consensus rating of “Hold” and an average price target of $28.36.

Insider Buying and Selling at Myriad Genetics

In other Myriad Genetics news, Director Heinrich Dreismann sold 10,000 shares of Myriad Genetics stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $27.05, for a total value of $270,500.00. Following the transaction, the director now owns 121,648 shares of the company’s stock, valued at approximately $3,290,578.40. The trade was a 7.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Colleen F. Reitan sold 46,012 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $27.95, for a total transaction of $1,286,035.40. Following the completion of the sale, the director now directly owns 42,533 shares in the company, valued at approximately $1,188,797.35. This represents a 51.96 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,012 shares of company stock valued at $1,900,485. 2.10% of the stock is currently owned by corporate insiders.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.